糖蛋白IIb/IIIa抑制剂替罗非班对急性冠脉综合征患者全血胆碱浓度的影响

IF 1 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Labmedicine Pub Date : 2015-09-23 DOI:10.1309/0TQB1HAUX9JFU1B0

C. Storm, O. Danne, C. Lueders, U. Frei, M. Möckel

{"title":"糖蛋白IIb/IIIa抑制剂替罗非班对急性冠脉综合征患者全血胆碱浓度的影响","authors":"C. Storm, O. Danne, C. Lueders, U. Frei, M. Möckel","doi":"10.1309/0TQB1HAUX9JFU1B0","DOIUrl":null,"url":null,"abstract":"Background Whole blood choline (WBCHO) concentrations reflect phospholipase D activation pathways involved in coronary plaque vulnerability and platelet activation suppressed by glycoprotein IIb/IIIa receptor (GP IIb/IIIa) inhibitors, but it is unknown whether this treatment affects serial WBCHO levels.\n\nMethods We performed a retrospective matched pairs analysis of 32 patients with acute coronary syndrome treated either with standard therapy alone or with tirofiban plus standard therapy with serial measurements of WBCHO.\n\nResults The median level of choline decreased after 4 to 6 hours in the tirofiban group (21.2 μmol/L) while the median level in the group without tirofiban increased (29.3 μmol/L) and WBCHO was significantly lower in tirofiban treated patients ( P =0.039). Over time, the decrease of WBCHO was significant in the tirofiban group only ( P =0.006).\n\nConclusions Our results suggest that in patients with acute coronary syndrome, tirofiban treatment is associated with a significant reduction of WBCHO concentration.","PeriodicalId":54328,"journal":{"name":"Labmedicine","volume":"48 1","pages":"349-355"},"PeriodicalIF":1.0000,"publicationDate":"2015-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of the Glycoprotein IIb/IIIa Inhibitor Tirofiban on Concentrations of Whole Blood Choline in Acute Coronary Syndromes\",\"authors\":\"C. Storm, O. Danne, C. Lueders, U. Frei, M. Möckel\",\"doi\":\"10.1309/0TQB1HAUX9JFU1B0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Whole blood choline (WBCHO) concentrations reflect phospholipase D activation pathways involved in coronary plaque vulnerability and platelet activation suppressed by glycoprotein IIb/IIIa receptor (GP IIb/IIIa) inhibitors, but it is unknown whether this treatment affects serial WBCHO levels.\\n\\nMethods We performed a retrospective matched pairs analysis of 32 patients with acute coronary syndrome treated either with standard therapy alone or with tirofiban plus standard therapy with serial measurements of WBCHO.\\n\\nResults The median level of choline decreased after 4 to 6 hours in the tirofiban group (21.2 μmol/L) while the median level in the group without tirofiban increased (29.3 μmol/L) and WBCHO was significantly lower in tirofiban treated patients ( P =0.039). Over time, the decrease of WBCHO was significant in the tirofiban group only ( P =0.006).\\n\\nConclusions Our results suggest that in patients with acute coronary syndrome, tirofiban treatment is associated with a significant reduction of WBCHO concentration.\",\"PeriodicalId\":54328,\"journal\":{\"name\":\"Labmedicine\",\"volume\":\"48 1\",\"pages\":\"349-355\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2015-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Labmedicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1309/0TQB1HAUX9JFU1B0\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Labmedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1309/0TQB1HAUX9JFU1B0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

全血胆碱(WBCHO)浓度反映了糖蛋白IIb/IIIa受体(GP IIb/IIIa)抑制剂抑制的冠状动脉斑块易损和血小板活化的磷脂酶D激活途径，但这种治疗是否影响系列WBCHO水平尚不清楚。方法对32例急性冠状动脉综合征患者进行回顾性配对分析，这些患者要么单独接受标准治疗，要么接受替罗非班加标准治疗，并连续测量WBCHO。结果替罗非班治疗4 ~ 6 h后，替罗非班组患者胆碱中位水平下降(21.2 μmol/L)，而未使用替罗非班组患者胆碱中位水平升高(29.3 μmol/L)， WBCHO显著降低(P =0.039)。随着时间的推移，只有替罗非班组的WBCHO降低显著(P =0.006)。结论:我们的研究结果表明，在急性冠脉综合征患者中，替罗非班治疗与WBCHO浓度的显著降低有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Effect of the Glycoprotein IIb/IIIa Inhibitor Tirofiban on Concentrations of Whole Blood Choline in Acute Coronary Syndromes

Background Whole blood choline (WBCHO) concentrations reflect phospholipase D activation pathways involved in coronary plaque vulnerability and platelet activation suppressed by glycoprotein IIb/IIIa receptor (GP IIb/IIIa) inhibitors, but it is unknown whether this treatment affects serial WBCHO levels. Methods We performed a retrospective matched pairs analysis of 32 patients with acute coronary syndrome treated either with standard therapy alone or with tirofiban plus standard therapy with serial measurements of WBCHO. Results The median level of choline decreased after 4 to 6 hours in the tirofiban group (21.2 μmol/L) while the median level in the group without tirofiban increased (29.3 μmol/L) and WBCHO was significantly lower in tirofiban treated patients ( P =0.039). Over time, the decrease of WBCHO was significant in the tirofiban group only ( P =0.006). Conclusions Our results suggest that in patients with acute coronary syndrome, tirofiban treatment is associated with a significant reduction of WBCHO concentration.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Labmedicine 医学-医学实验技术

CiteScore

2.50

自引率

0.00%

发文量

155

审稿时长

>12 weeks

期刊介绍： Lab Medicine is a peer-reviewed biomedical journal published quarterly by the ASCP and Oxford University Press. The journal invites submission of manuscripts on topics related to clinical chemistry and microbiology, hematology, immunology, transfusion medicine, molecular diagnostics, cytology, histology, and laboratory administration and management. Original research, reviews, and case reports are considered for publication. Lab Medicine is indexed (under the title Laboratory Medicine) by the National Library of Medicine and is included in the PubMed database.